In lung adenocarcinoma, recent studies have confirmed that AXL inhibition decreased the expression of PD-L1 and CXC chemokine receptor 6 (CXCR6), especially when EGFR was mutated [38]. This evidence concerns the gene EGFR and lung adenocarcinoma.